

S4 Table. Matched therapy and therapeutic response in patients with additionally identified targetable alterations

ID	Sex	Age (yr)	Gene	Alterations	Targeted agent	Therapeutic response
A02	F	48	<i>EGFR</i>	Exon19del	Erlotinib	Complete
A03	F	51	<i>EGFR</i>	Exon19del	Iretinib	Partial
A04	F	44	<i>EGFR</i>	Exon19del	Gefitinib	Partial
A06	M	61	<i>EGFR</i>	Exon20ins	JNJ-61186372	Unknown
A07	F	60	<i>EGFR</i>	Exon20ins	JNJ-61186372	Partial
A08	F	46	<i>EGFR</i>	Exon20ins	JNJ-61186372	Unknown
A09	M	64	<i>EGFR</i>	Exon20ins	JNJ-61186372	Unknown
A11	F	63	<i>EGFR</i>	L858R	Gefitinib	Partial
A12	F	73	<i>EGFR</i>	L858R	Gefitinib	Stable
A13	M	58	<i>EGFR</i>	L858R	Gefitinib	Stable
A14	F	68	<i>EGFR</i>	L858R	Gefitinib	Stable
A15	M	68	<i>EGFR</i>	L858R	Gefitinib	Partial
B2	F	44	<i>ALK</i>	<i>EML4-ALK</i>	Crizotinib	Partial
B9	F	66	<i>ALK</i>	<i>EML4-ALK</i>	Alectinib	Partial
C1	F	47	<i>ROS1</i>	<i>CD74-ROS1</i>	Ceritinib	Partial
C2	F	69	<i>ROS1</i>	<i>SDC4-ROS1</i>	Repotrectinib	Stable
D140	F	54	<i>RET</i>	<i>KIF5B-RET</i>	Selpercatinib	Partial
D145	F	65	<i>RET</i>	<i>CCDC6-RET</i>	Selpercatinib	Stable
D170	F	71	<i>RET</i>	<i>CCDC6-RET</i>	Selpercatinib	Unknown
D196	F	54	<i>RET</i>	<i>KIF5B-RET</i>	Selpercatinib	Unknown
D199	F	72	<i>RET</i>	<i>KIF5B-RET</i>	Selpercatinib	Complete
D203	M	63	<i>RET</i>	<i>KIF5B-RET</i>	Selpercatinib	Stable
D218	M	60	<i>RET</i>	<i>KIF5B-RET</i>	Selpercatinib	Partial
D148	F	66	<i>MET</i>	Exon14 skipping and amplification	TAS-115	Partial
D197	F	78	<i>MET</i>	Exon14 skipping	TAS-115	Partial
D239	F	81	<i>MET</i>	Exon14 skipping	Capmatinib	Stable
D155	F	57	<i>BRAF</i>	V600E	Dabrafenib/Tametinib	Partial
D191	M	67	<i>BRAF</i>	V600E	Dabrafenib/Tametinib	Stable
D202	F	62	<i>BRAF</i>	V600E	Dabrafenib/Tametinib	Stable
D223	F	61	<i>BRAF</i>	V600E	Dabrafenib/Tametinib	Stable